Which resource helps pharmacists determine if biological products are interchangeable biosimilars?

The Purple Book is the key resource that assists pharmacists in determining if biological products are interchangeable biosimilars. It is published by the U.S. Food and Drug Administration (FDA) and provides information on licensed biological products, including which biosimilars may be considered interchangeable with their reference products.

The significance of the Purple Book lies in its focus on biosimilar products and their therapeutic equivalence, which is crucial for pharmacists when making decisions about medication substitutions. Understanding which biosimilars are interchangeable helps ensure that pharmacists dispense the correct medication while maintaining patient safety and efficacy.

Other resources, like the Green Book, Blue Book, and Orange Book, address different categories of medications and provide information on drug evaluations and therapeutic equivalency, but they do not specifically relate to the interchangeability of biological products.